Daily Archives: August 4, 2022

Counties with highest COVID-19 infection rates in Rhode Island – What’sUpNewp

Posted: August 4, 2022 at 2:36 pm

Stacker compiled a list of the counties with highest COVID-19 infection rates in Rhode Island using data from the U.S. Department of Health & Human Services and vaccination data from Covid Act Now. Counties are ranked by the highest infection rate per 100,000 residents within the week leading up to August 2, 2022. Cumulative cases per 100,000 served as a tiebreaker.

Keep reading to see whether your county ranks among the highest COVID-19 infection rates in your state.

New cases per 100k in the past week: 140 (115 new cases, +19% change from previous week) Cumulative cases per 100k: 28,300 (23,229 total cases) 23.3% less cases per 100k residents than Rhode Island Cumulative deaths per 100k: 117 (96 total deaths) 65.9% less deaths per 100k residents than Rhode Island Population that is fully vaccinated: 76.2% (62,552 fully vaccinated)

New cases per 100k in the past week: 147 (185 new cases, -4% change from previous week) Cumulative cases per 100k: 29,818 (37,445 total cases) 19.2% less cases per 100k residents than Rhode Island Cumulative deaths per 100k: 193 (242 total deaths) 43.7% less deaths per 100k residents than Rhode Island Population that is fully vaccinated: 80.0% (100,413 fully vaccinated)

New cases per 100k in the past week: 153 (74 new cases, -16% change from previous week) Cumulative cases per 100k: 32,348 (15,682 total cases) 12.4% less cases per 100k residents than Rhode Island Cumulative deaths per 100k: 369 (179 total deaths) 7.6% more deaths per 100k residents than Rhode Island Population that is fully vaccinated: 79.9% (38,755 fully vaccinated)

New cases per 100k in the past week: 166 (1,059 new cases, -4% change from previous week) Cumulative cases per 100k: 38,429 (245,536 total cases) 4.1% more cases per 100k residents than Rhode Island Cumulative deaths per 100k: 405 (2,586 total deaths) 18.1% more deaths per 100k residents than Rhode Island Population that is fully vaccinated: 71.7% (458,022 fully vaccinated)

New cases per 100k in the past week: 194 (319 new cases, +4% change from previous week) Cumulative cases per 100k: 33,936 (55,754 total cases) 8.1% less cases per 100k residents than Rhode Island Cumulative deaths per 100k: 317 (520 total deaths) 7.6% less deaths per 100k residents than Rhode Island Population that is fully vaccinated: 79.5% (130,530 fully vaccinated)

See more here:

Counties with highest COVID-19 infection rates in Rhode Island - What'sUpNewp

Posted in Covid-19 | Comments Off on Counties with highest COVID-19 infection rates in Rhode Island – What’sUpNewp

A first update on mapping the human genetic architecture of COVID-19 – Nature.com

Posted: at 2:36 pm

Yale University, New Haven, CT, USA

Gita A. Pathak&Renato Polimanti

Institute for Molecular Medicine Finland (FIMM), Univerisity of Helsinki, Helsinki, Finland

Juha Karjalainen,Mark Daly,Andrea Ganna&Mark J. Daly

Broad Institute of MIT and Harvard, Cambridge, MA, USA

Christine Stevens,Mark Daly,Andrea Ganna,Masahiro Kanai,Rachel G. Liao,Amy Trankiem,Mary K. Balaconis,Huy Nguyen,Matthew Solomonson,Kumar Veerapen,Samuli Ripatti,Lindo Nkambul,Mark J. Daly,Sam Bryant&Vijay G. Sankaran

Massachusetts General Hospital, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Benjamin M. Neale

Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA

Mark Daly,Andrea Ganna,Konrad J. Karczewski,Alicia R. Martin,Elizabeth G. Atkinson,Masahiro Kanai,Kristin Tsuo,Nikolas Baya,Patrick Turley,Rahul Gupta,Raymond K. Walters,Duncan S. Palmer,Gopal Sarma,Matthew Solomonson,Nathan Cheng,Wenhan Lu,Claire Churchhouse,Jacqueline I. Goldstein,Daniel King,Wei Zhou,Cotton Seed,Mark J. Daly,Benjamin M. Neale,Hilary Finucane,F. Kyle Satterstrom&Sam Bryant

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Shea J. Andrews,Laura G. Sloofman,Stuart C. Sealfon,Clive Hoggart&Slayton J. Underwood

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

Mattia Cordioli,Matti Pirinen,Kati Donner,Katja Kivinen,Aarno Palotie&Mari Kaunisto

Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, York City, NY, USA

Nadia Harerimana

Centre for Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland

Karolina Chwialkowska

University of Michigan, Ann Arbor, MI, USA

Brooke Wolford

Ancestry, Lehi, UT, USA

Genevieve Roberts,Danny Park,Catherine A. Ball,Marie Coignet,Shannon McCurdy,Spencer Knight,Raghavendran Partha,Brooke Rhead,Miao Zhang,Nathan Berkowitz,Michael Gaddis,Keith Noto,Luong Ruiz,Milos Pavlovic,Eurie L. Hong,Kristin Rand,Ahna Girshick,Harendra Guturu&Asher Haug Baltzell

Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland

Mari E. K. Niemi&Sara Pigazzini

University of Liege, GIGA-Institute, Lige, Belgium

Souad Rahmouni,Michel Georges&Yasmine Belhaj

CHC Mont-Lgia, Lige, Belgium

Julien Guntz&Sabine Claassen

5BHUL (Lige Biobank), CHU of Lige, Lige, Belgium

Yves Beguin&Stphanie Gofflot

Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

Mattia Cordioli

Analytic & Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA

Lindokuhle Nkambule,Lindokuhle Nkambul,Lindokuhle Nkambule&Lindo Nkambul

Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Lindokuhle Nkambule

Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Lindokuhle Nkambule,Konrad J. Karczewski,Alicia R. Martin,Elizabeth G. Atkinson,Masahiro Kanai,Kristin Tsuo,Nikolas Baya,Patrick Turley,Rahul Gupta,Raymond K. Walters,Duncan S. Palmer,Gopal Sarma,Matthew Solomonson,Nathan Cheng,Wenhan Lu,Claire Churchhouse,Jacqueline I. Goldstein,Daniel King,Wei Zhou,Cotton Seed,Benjamin M. Neale,Hilary Finucane,F. Kyle Satterstrom,Sam Bryant&Caroline Cusick

CHU of Liege, Lige, Belgium

Michel Moutschen,Benoit Misset,Gilles Darcis,Julien Guiot,Samira Azarzar,Olivier Malaise,Pascale Huynen,Christelle Meuris,Marie Thys,Jessica Jacques,Philippe Lonard,Frederic Frippiat,Jean-Baptiste Giot,Anne-Sophie Sauvage,Christian Von Frenckell&Bernard Lambermont

University of Liege, Lige, Belgium

Michel Moutschen,Benoit Misset,Gilles Darcis,Julien Guiot&Samira Azarzar

Department of Human Genetics, McGill University, Montreal, Quebec, Canada

Tomoko Nakanishi

Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada

Tomoko Nakanishi,David R. Morrison,J. Brent Richards,Guillaume Butler-Laporte,Vincenzo Forgetta,Biswarup Ghosh,Laetitia Laurent,Danielle Henry,Tala Abdullah,Olumide Adeleye,Noor Mamlouk,Nofar Kimchi,Zaman Afrasiabi,Nardin Rezk,Branka Vulesevic,Meriem Bouab,Charlotte Guzman,Louis Petitjean,Chris Tselios,Xiaoqing Xue,Jonathan Afilalo&Darin Adra

Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Tomoko Nakanishi

Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan

Tomoko Nakanishi

McGill Genome Centre and Department of Human Genetics, McGill University, Montreal, Quebec, Canada

Vincent Mooser,Rui Li,Alexandre Belisle,Pierre Lepage,Jiannis Ragoussis,Daniel Auld&G. Mark Lathrop

Department of Human Genetics, Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

J. Brent Richards

Department of Twin Research, Kings College London, London, UK

J. Brent Richards

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montral, Qubec, Canada

Guillaume Butler-Laporte

Department of Emergency Medicine, McGill University, Montreal, Quebec, Canada

Marc Afilalo

Emergency Department, Jewish General Hospital, McGill University, Montreal, Quebec, Canada

Marc Afilalo

McGill AIDS Centre, Department of Microbiology and Immunology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada

Maureen Oliveira

McGill Centre for Viral Diseases, Lady Davis Institute, Department of Infectious Disease, Jewish General Hospital, Montreal, Quebec, Canada

Bluma Brenner

Research Centre of the Centre Hospitalier de lUniversit de Montral, Montreal, Canada

Nathalie Brassard

Department of Medicine, Research Centre of the Centre Hospitalier de lUniversit de Montral, Montreal, Canada

Madeleine Durand

Department of Medicine, Universit de Montral, Montreal, Canada

Madeleine Durand,Michal Chass&Daniel E. Kaufmann

Department of Medicine and Human Genetics, McGill University, Montreal, Quebec, Canada

Erwin Schurr

Department of Intensive Care, Research Centre of the Centre Hospitalier de lUniversit de Montral, Montreal, Quebec, Canada

Michal Chass

Division of Infectious Diseases, Research Centre of the Centre Hospitalier de lUniversit de Montral, Montreal, Quebec, Canada

Daniel E. Kaufmann

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK

Caroline Hayward,Anne Richmond&J. Kenneth Baillie

Center for Applied Genomics, Childrens Hospital of Philadelphia, Philadelphia, PA, USA

Joseph T. Glessner,Hakon Hakonarson&Xiao Chang

Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Joseph T. Glessner&Hakon Hakonarson

Vanderbilt University Medical Center, Nashville, TN, USA

Douglas M. Shaw,Jennifer Below,Hannah Polikowski,Petty E. Lauren,Hung-Hsin Chen,Zhu Wanying,Lea Davis&V. Eric Kerchberger

Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK

Archie Campbell,David J. Porteous&Chloe Fawns-Ritchie

Usher Institute, University of Edinburgh, Nine, Edinburgh Bioquarter, Edinburgh, UK

Archie Campbell

University of Texas Health, Houston, TX, USA

Marcela Morris&Joseph B. McCormick

Department of Psychology, University of Edinburgh, Edinburgh, UK

Chloe Fawns-Ritchie&Chloe Fawns-Ritchie

University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Kari North

Center for Applied Genomics, The Childrens Hospital of Philadelphia, Philadelphia, PA, USA

Xiao Chang,Joseph R. Glessner&Hakon Hakonarson

Division of Human Genetics, Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Joseph R. Glessner

Continued here:

A first update on mapping the human genetic architecture of COVID-19 - Nature.com

Posted in Covid-19 | Comments Off on A first update on mapping the human genetic architecture of COVID-19 – Nature.com

Pedagogies, Communities, and Practices of Care after COVID-19 – Knox College

Posted: at 2:36 pm

The Mellon Foundation awarded $150,000 to Knox College for a research project entitled Pedagogies, Communities, and Practices of Care after COVID-19. Cate Denial, Bright Distinguished Professor of American History, chair of History, and director of the Bright Institute, is the principal investigator.

Over the past two years, administrators, faculty, and staff have held higher education together with willpower and determination in the face of a global pandemic. The result, for many, has been burnout and exhaustion. This project responds to that crisis with a plan to identify, cultivate, and support national leadership in applying practices of compassion and care to working conditions in higher education. Denial will coordinate 36 individuals from community colleges, four-year institutions, regional states, and flagship research institutions, including online educators. These individuals, representing diverse social identities, will explore the meaning of, and opportunities within, a practice of care in the academy.

Im so grateful for the encouragement and support of the Mellon Foundation in funding this project, said Denial. Care and compassion offer a strong foundation from which to build, change, and rethink community as the pandemic continues. Faculty and staff working conditions are student learning conditions, making it particularly important to think critically about the ways in which we labor, and new approaches to work that will increase accessibility, employ trauma-informed practices, and evolve our pedagogies to affirm that care is at the center of what we do.

View post:

Pedagogies, Communities, and Practices of Care after COVID-19 - Knox College

Posted in Covid-19 | Comments Off on Pedagogies, Communities, and Practices of Care after COVID-19 – Knox College

God, No, Not Another Case. COVID-Related Stillbirths Didn’t Have to Happen. – ProPublica

Posted: at 2:36 pm

This story contains descriptions of stillbirths.

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up for Dispatches, a newsletter that spotlights wrongdoing around the country, to receive our stories in your inbox every week.

Late one afternoon last October, Dr. Shelley Odronic sat in her office and, just as she had thousands of times before, slid a rectangular glass slide onto her microscope.

A pathologist who works in rural Ohio, Odronic leaned forward to examine tissue from the placenta of a woman who had recently given birth. She increased the magnification on the microscope. Never had she seen so many tiny, congealed reservoirs of blood or such severe inflammation of the tissue, a sign the placenta had been fighting an infection.

Right away, I knew it wasnt compatible with life, Odronic said.

She asked her secretary to print out the patients chart. In dark letters were the words fetal demise. A stillbirth, the death of a fetus at 20 weeks or more of pregnancy. But that didnt solve the mystery. Odronic had examined many placentas from pregnancies that ended in stillbirth. None looked like this withered and scarred.

Odronic kept reading. No chronic medical conditions. Good prenatal care. Then, buried in the middle of the report, she spotted something. Seven days before the stillbirth, the mother had tested positive for COVID-19. Odronic wondered if the virus could explain the damage to the placenta. In the world of placenta pathology, a new affliction is unusual, especially one so dramatic in presentation and so devastating in effect.

Her mind traveled to Dr. Amy Heerema-McKenney, a pathologist at Cleveland Clinic and an expert on the placenta, who had trained Odronic during residency. Odronic went to sleep that night with a pit in her stomach and a plan to call her former teacher in the morning.

Heerema-McKenney was in her office when the phone rang. As she listened, she knew that what Odronic was describing was what she and her colleagues had observed repeatedly over the past several months: a patient positive for the coronavirus, a placenta destroyed by COVID-19, a baby stillborn.

Their next discovery was equally stunning. None of the stillbirths they studied involved a pregnant person who had been fully vaccinated. The doctors checked with colleagues across the country and around the world. The fatal pattern held.

Unvaccinated women who contracted COVID-19 during pregnancy were at a higher risk of stillbirths. They also were more likely to be admitted to the intensive care unit, give birth prematurely or die. Yet their greatest protection the COVID-19 vaccine sat largely untouched, buried under doubt, polluted by disinformation.

How Misinformation About COVID Vaccines and Pregnancy Took Root Early On and Why It Wont Go Away

Pharmaceutical companies and government officials failed to ensure that pregnant people were included in the early development of the COVID-19 vaccine, a calamitous decision made amid the urgency of a rapidly spreading pandemic. That decision left pregnant people with little research to rely on when making a critical decision on how best to keep the babies growing inside of them safe.

At the same time that research was excluding pregnant people from vaccine trials, a full-scale assault on vaccination was unfolding online. Taking advantage of the lack of data, conspiracy theorists, anti-vaxxers and even some medical professionals spread false claims about the vaccines safety in pregnancy, leading many pregnant people to delay or refuse the vaccine. Even now, with numerous studies unequivocally announcing the safety of the vaccine for pregnant people, some doctors have failed to communicate the dangers of COVID-19 to pregnant people or the vaccines role in mitigating it.

The Centers for Disease Control and Prevention contributed to the confusion with vague early messaging about whether pregnant people should get vaccinated. While Americans lined up at pharmacies and stalked vaccine websites in hopes of securing a shot last year, pregnant people had some of the lowest vaccination rates among adults, with only 35% fully vaccinated by last November. Meanwhile, many Americans were already moving on to their boosters after federal officials that month expanded eligibility for the additional shots to anyone 18 or older. And much of the country was beginning to return to pre-pandemic life. The Sunday after Thanksgiving, for instance, set the record for the busiest day of air travel since March 2020.

November also marked a key moment in the understanding of COVID-19s impact on stillbirths. A CDC study looking at 1.2 million births in the first 18 months of the pandemic found that more than 8,000 pregnancies ended in stillbirths, including more than 270 of them in patients with a documented COVID-19 diagnosis at the time of delivery.

Although stillbirths were rare overall, babies were dying. The risk of a stillbirth nearly doubled for those who had COVID-19 during pregnancy compared with those who didnt. And during the spread of the delta variant, that risk was four times higher.

Indeed, doctors discovered that some stillbirths resulted from COVID-19 directly infiltrating the placenta, a condition they named SARS-CoV-2 placentitis. Cases were found even in people whose COVID-19 symptoms were mild or nonexistent. In some cases, however, placentas were discarded with medical waste without being tested for COVID-19, and parents never learned what led to their babys stillbirth.

COVID-19 also led to stillbirths among pregnant people who became exceedingly ill after contracting the virus. It damaged their lungs and clotted their blood, putting their babies in such severe distress that they were born before they could take their first breath.

These are pregnancies that should not have ended, Heerema-McKenney said.

She and others had tried to alert the CDC as well as maternal and state health organizations to their findings, but she said they either didnt get a response or were told they needed to collect more data and publish studies. Pathologists are experts in disease diagnosis, dealing with death and illness from the safe distance of their labs. Convincing obstetricians who met with patients daily or doctors who were making policy recommendations was a challenge.

I tried to sound the alarm. We tried so hard to get people to listen, Heerema-McKenney said. It was a really frustrating place to be as pathologists doing these autopsies, looking at these placentas and saying, God, no, not another case.

Around the same time Heerema-McKenney was examining the damaged placentas, Ginger Munro was on life support in a hospital 250 miles away in another part of Ohio.

She and her husband, Kendal, had been trying to have a child for five years. They hadnt expected that shed get pregnant in the middle of a pandemic. But when her pregnancy test came back positive in the spring of 2021, she rushed to post a picture of it in an online pregnancy group. Is it just me or can you see the 2 lines?? she asked.

The pandemic had already brought much change to their lives. Ginger, who lives in the small town of Washington Court House in southwest Ohio, quit her job as assistant nutrition director with the countys Commission on Aging. She stationed hand sanitizer throughout her house and in her car, and she only went grocery shopping early in the morning. If she noticed someone in an aisle, she skipped it.

I knew the virus was real, she said, but I was terrified to take the vaccine.

Ginger worried that the vaccines development had been rushed, and she hadnt seen any data showing it was safe for pregnant people. At this point, the CDC had not explicitly recommended the vaccine during pregnancy. Ginger already worried she was tempting fate by getting pregnant at 40; she said she didnt want to risk endangering her baby by taking the vaccine.

Besides, if it was really important, her doctor would have mentioned it, and, she said, she would have followed his advice. But, she said, he never did. Her family hadnt gotten vaccinated either. In a mostly rural county where less than half of the residents were vaccinated, they were hardly alone.

Her doctor declined to comment through a spokesperson at the hospital system where he works; the spokesperson said the hospital couldnt disseminate information about the vaccine to pregnant patients before it was recommended.

Gingers pregnancy progressed without complications. She and Kendal shared the news of a new baby with Gingers two daughters from a previous marriage. At their kitchen table, near a sign that read eat cake for breakfast, Sophia, then 14, covered her mouth with both hands while Hailee, then 18, simply beamed.

At a backyard gender reveal three months later, Gingers growing belly resembled a basketball against her tiny frame. She leaned in to kiss her husband, her long, dark hair falling onto her shoulders. Red confetti rained down on the deck.

Kendal, an aircraft maintenance and avionics manager at an airport two counties away, worked through the pandemic. In the summer, when they realized his cough was actually COVID-19, it was too late. Ginger was sick.

What the Placenta Does

The placentas job is as critical as it is clear: keep the baby alive.

For the most part, it does that well. The placenta is the first organ to develop after conception, and it connects to the fetus through the umbilical cord, which delivers oxygen. The placenta provides nourishment, expels waste and does much of the work of the fetuss lungs, kidneys and liver as they develop. The dark-red organ typically is solid, with a sponge-like texture and blood vessels that spread out like the branches of a tree.

The placenta also acts as a shield against most viruses, but when its attacked by COVID-19, the branches can collapse, killing the cells, cutting off oxygen to the fetus, leaving holes to be filled by pools of blood. In response to the infected and dying cells, inflammation and scarring spread throughout the placenta.

Unable to survive the damage to the placenta, many babies were stillborn.

Having trouble reaching her doctor, she went to two different emergency rooms. One, she said, declined to treat her with monoclonal antibodies, which research had shown can be an effective treatment for pregnant people with COVID-19. The other, which described her in medical records as an exceedingly pleasant individual admitted with symptomatic COVID-19 pneumonia, transferred her about an hour away to the University of Cincinnati Medical Center. There, records show, she was admitted with acute respiratory distress syndrome due to COVID-19.

The University of Cincinnati doctor asked Ginger and Kendal who was on FaceTime because of the hospitals COVID-19 protocols about fetal priority. Ginger made her wishes clear: Save the baby, their baby, the baby they had tried so hard to have. Kendal, who was worried about both his wife and their unborn child, said he went along with Ginger in that moment.

You were so scared, Kendal wrote in a notebook that night. We told each other over and over how much we loved each other.

They hung up so the doctors could insert a breathing tube. Before they could begin, Kendal called back three more times just to hear her voice.

Doctors put Ginger on ECMO, a form of life support reserved for the sickest patients. Kendal, Hailee, Sophia and Gingers mother and sister were later allowed in the hospital two at a time, and they prayed at her bedside nearly every night. Ginger was sedated, her face swollen and obscured by tubing, her cheeks flattened by the crush of the ventilator straps, her wrists tied down so she wouldnt accidentally pull out her breathing tube.

Her family took solace in knowing the babys heartbeat was steady and her ultrasounds were normal. The doctors gave Ginger medication to help the babys lungs mature in case she was born early. After more than 30 days on ECMO, doctors took Ginger off the machine only to put her back on the next morning. She was the first patient in the hospitals history to be placed on ECMO twice.

The plan, records show, was to deliver at 28 weeks. But the day after Ginger was put back on life support, Kendal got the call telling him the baby was on her way. As doctors prepared for the delivery in Gingers intensive care room, the family camped out in the waiting room, jittery from excitement and vending machine snacks. They talked about baby names and future family outings. They pulled the waiting room chairs together to form makeshift beds and covered themselves with blankets they brought from home.

They dont know if they actually fell asleep before a nurse burst through the doors screaming at them to follow. Shes coming! Shes coming! They didnt make it far before they were blocked by doctors and nurses, some huddled over an incubator in the middle of the hall and the rest crowded around Ginger.

Hailee tried to peer over the sea of blue scrubs to catch the first glimpse of her little sister. She smiled beneath her black mask. Shell be OK, she said to herself.

But after a few minutes of trying to revive the baby, a doctor told Kendal it was time. Kendal nodded, asked for a chair and collapsed as he tried to process his daughters death.

Then another wave of grief washed over him. Someone would have to tell Ginger.

Content Warning

Warning: The following image shows a stillborn baby. The Munro family had photos taken of their daughter to preserve their memory of her.

Gingers medical records describe a baby born at 27 weeks without signs of life after an uncomplicated delivery. Her placenta had separated from the wall of the uterus, the risk of which studies have shown increases with COVID-19.

When Ginger woke up, she looked down at her sunken belly and realized she had given birth. She assumed her daughter was in the newborn intensive care unit. Ginger was barely able to speak around the tube in her trachea, but after a few days in which no one brought the baby to her, she couldnt wait any longer. Ginger turned to her mother and sister and mouthed the words, Wheres the baby?

The room fell silent. They called Kendal, who rushed to the hospital. He told her what had happened. He described their daughters dark hair and her long fingers and toes, just like her mothers.

Ginger, who had always loved the sweet smell of a newborns breath, whispered to her husband.

Did you smell her breath?

She wasnt breathing, he said.

In the hurried quest for a safe and effective COVID-19 vaccine, pharmaceutical companies and government officials did not include pregnant people in their initial plans. Its a failure that continues to reverberate.

They absolutely should have been included in COVID vaccine trials from the beginning, said Kathryn Schubert, president and CEO of the Society for Womens Health Research, a Washington, D.C.-based nonprofit that advocates for the inclusion of women in research and clinical trials.

Researchers and advocates have spent more than four decades trying to dismantle the belief that its unsafe or unethical for pregnant women to participate in clinical trials. A couple years ago, it seemed like they had finally prevailed.

Shortly before leaving office, President Barack Obama signed into law the 21st Century Cures Act, which established the Task Force on Research Specific to Pregnant Women and Lactating Women. The group found longstanding obstacles, including liability concerns, to including pregnant and lactating people in clinical research. It concluded that recommending halting medication or forgoing treatment while pregnant may actually endanger the health of the mother and her fetus more than the treatment itself.

The need for everything from asthma to depression medication doesnt stop when a person gets pregnant, and when a catastrophic event such as a pandemic hits, experts said, pregnancy should not preclude someone from receiving life-saving treatment.

Around the same time, researchers discovered that the Zika virus, which was mainly transmitted through mosquitoes, could pass from a pregnant person to their fetus and cause severe birth deformities. A second group of experts joined together to develop separate guidance on including pregnant people in the research, development and deployment of pandemic vaccines.

Both groups pushed to remove pregnant women from a list of vulnerable populations that required additional review before being allowed to participate in research. Instead of proving that pregnant women should be included, manufacturers would need to provide compelling evidence for why they shouldnt.

In 2018, the federal task force issued recommendations calling for including pregnant and breastfeeding people in biomedical research, and the Department of Health and Human Services adopted some of the guidance. But a gap remained between what the task force and others insisted was needed and what was actually happening.

We were frustrated because COVID-19 provided an opportunity to implement the recommendations of the task force, said Dr. Diana Bianchi, the director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the chair of the task force.

In February 2021, Bianchi and her colleagues published an article lamenting the exclusion of those who were pregnant or breastfeeding from the initial COVID-19 vaccine clinical trials. Pregnant and lactating persons should not be protected from participating in research, but rather should be protected through research, they wrote.

Ruth Faden, the founder of the Johns Hopkins Berman Institute of Bioethics, helped lead the group that issued the guidance after Zika. She and others urged manufacturers to include pregnant people in the development of the COVID-19 vaccine as part of Operation Warp Speed, the federal program that provided billions of taxpayer dollars to pharmaceutical companies to speed up vaccine production.

There is a playbook in place so that when the U.S. launches Operation Warp Speed, it should be pretty obvious what should be done, she said. Its not like no one knows how to do this, either ethically or technically.

Nevertheless, it doesnt happen, Faden added. Once again, pregnant people are left behind.

A spokesperson for Pfizer said the company followed guidance from the Food and Drug Administration. Although pregnant people were not included in the initial vaccine clinical trials, Pfizer tested its vaccine on pregnant rats and did not identify any safety concerns. The company subsequently launched a clinical trial with pregnant women but halted it because at that point the vaccine had already been recommended for pregnant people.

Similarly, Moderna also studied its vaccine on pregnant animals, but the company said it made the decision to prioritize the study of the safety and efficacy of the vaccine in adults who werent pregnant. It called that approach consistent with the precedent to study new vaccines in pregnant women only after demonstration of favorable benefit and risk in healthy adults.

In response to questions from ProPublica, Johnson & Johnson referred a reporter to its website, which didnt address the relevant issues.

Some government officials, including several from the Food and Drug Administration, said they support having pregnant women take part in clinical studies of vaccines for emerging infectious disease, including COVID-19. A spokesperson for the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, said the agency did not dictate the protocol development for the trials and said that responsibility lies with the companies.

The failure to include pregnant people early on in COVID-19 vaccine trials was, at least in part, a casualty of the tremendous urgency to respond to an intense public threat and develop the vaccine as quickly as possible, Faden said. But multiple groups had published road maps on how to ethically include pregnant people without slowing down that process.

I cant tell you how many pregnant people might not have died or how many stillbirths might not have occurred if the playbook had been followed, she said, but Im willing to bet it was a significant chunk that would have been prevented if there had been a full-throated, evidence-based recommendation for COVID-19 vaccines in pregnancy almost simultaneous to when it was available for the rest of the adult population.

By the time the CDC specifically recommended the vaccine for pregnant people, in August 2021, the damage had been done.

A dizzying and vague series of advisories led to confusion and delayed vaccinations. When the COVID-19 vaccines were first made available in December 2020, the CDC said health care workers and residents of long-term care facilities should be prioritized, but the shots were not explicitly recommended for pregnant people. Instead, the agency said on its webpage for vaccines and pregnancy that pregnant health care workers may choose to be vaccinated. In explaining that decision, the CDC said that experts had considered how mRNA vaccines, which do not contain the live virus, work. They concluded that the vaccines are unlikely to pose a risk for people who are pregnant.

However, the CDC added, the potential risks of mRNA vaccines to the pregnant person and her fetus are unknown because these vaccines have not been studied in pregnant women.

In January, the World Health Organization recommended against pregnant people getting the vaccine unless they faced increased risk, such as complicating comorbidities or exposure to the virus due to a job in health care, but the agency later reversed course.

A few months later, in March 2021, the CDC continued its lukewarm messaging that pregnant people may choose to be vaccinated. The agency listed some points for pregnant people to consider discussing with their health care providers, starting with how likely they are to be exposed to COVID-19.

After a promising study showed that the vaccine was safe for pregnant people, CDC Director Dr. Rochelle Walensky said at a White House briefing in late April that the CDC was recommending the vaccine for them. But the CDC did not update its website to reflect her comments and said the agencys guidance had not changed: Pregnant people may choose to be vaccinated.

Once again, pregnant people were put in the precarious position of receiving ambiguous and inconsistent recommendations. In May 2021, the CDC reiterated that pregnant people faced an increased risk of getting severely ill from COVID-19, but the language surrounding the vaccine If you are pregnant, you can receive a COVID-19 vaccine was noncommittal.

A CDC spokesperson, responding to questions from ProPublica, said in an email that pregnant people were part of the first recommendations in December 2020 that encouraged people 16 and older to get vaccinated. At that time, data about the safety and efficacy of the vaccine during pregnancy was limited because pregnant people had been excluded from pre-authorization clinical trials, so the CDC included additional supporting language for pregnant people, saying they were eligible and could choose to receive the vaccine. The agency said its recommendations were based on available evidence and evolved throughout the pandemic.

Before making changes to its guidance, the CDC had its team of scientists review available data to ensure that there was an abundance of evidence.

For each update to the statement of risks during pregnancy, multiple types of studies and the strength of evidence for each were reviewed, another CDC spokesperson said. These reviews of the evidence were accompanied with discussions among subject matter experts both internally and externally with clinical partners for an ultimate determination of risk.

Dr. Cynthia Gyamfi-Bannerman, a perinatologist and chair of the department of obstetrics, gynecology and reproductive sciences at the University of California, San Diego School of Medicine, shared the daunting task of making vaccine recommendations for pregnant people as part of COVID-19 task forces for two leading organizations, The American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine.

In the beginning, she said, the only pregnancy-specific data they had came from a few dozen participants who were inadvertently included after becoming pregnant during the clinical trials and from some pregnant animal data.

It played out in real time in the COVID pandemic because we see the effects of not including pregnant people in these trials, Gyamfi-Bannerman said. We couldnt make a strong recommendation, so pregnant people were hesitant. I think that directly led to fewer people using the vaccine than we would have wanted.

At the end of June 2021, the CDC added a general update to its website to reflect the dangers of the delta variant tearing across much of the country. Getting vaccinated prevents severe illness, hospitalizations, and death, it wrote. Unvaccinated people should get vaccinated and continue masking until they are fully vaccinated.

But it wasnt until Aug. 11, eight months after the first vaccine was administered, that the CDC issued its formal recommendation that pregnant and breastfeeding people get vaccinated.

The vaccines are safe and effective, Walensky said in a statement at the time, and it has never been more urgent to increase vaccinations as we face the highly transmissible Delta variant and see severe outcomes from COVID-19 among unvaccinated pregnant people.

August would prove to be the deadliest month for COVID-19-related deaths of pregnant people. The CDC issued an emergency call the next month strongly recommending the vaccine to pregnant people, noting that approximately 97% of pregnant people hospitalized with COVID-19 were unvaccinated. The dangers to symptomatic pregnant people included a 70% increased risk of death, and their developing babies could face a host of perils, including stillbirths.

Researchers have yet to determine exactly why some pregnant people with COVID-19, vaccinated and unvaccinated alike, deliver stillborn babies, while others do not. Attempts to answer that question have been hindered, in part, by incomplete data. The CDCs statistics on COVID-19-related fetal and maternal deaths are undercounts. The CDC has data on less than 73,000 birth outcomes following a mothers confirmed COVID-19 diagnosis in 2020 and 2021, of which 579 were pregnancy losses.

That information was sent in by fewer than three dozen health departments, and those estimates dont include states like Mississippi, which in September reported 72 COVID-19-related stillbirths since the start of the pandemic, nearly double what the state would have expected, according to data from the Mississippi State Department of Health. Preliminary state data shows total stillbirths increased there in 2020 then dipped in 2021, but were still higher than pre-pandemic numbers.

A separate CDC database shows more than 220,000 COVID-19 cases and at least 305 deaths among pregnant people.

CDC recognizes that pregnant people faced challenging decisions about how to best protect themselves in the setting of uncertainty related to both the infection and the COVID-19 vaccine, a CDC spokesperson said, adding, COVID-19 vaccination remains one of the best ways to protect yourself and your family from serious illness from COVID-19.

Heartbroken and determined, Jaime Butcher has emerged as an unofficial ambassador for the vaccine, posting in online pregnancy and stillbirth forums about the risks of being pregnant and unvaccinated.

No one, she said, told her of the risks. Doctors, the CDC and health officials, she continued, arent doing enough to inform people. Even now, well into the pandemics third year, the message still isnt getting through.

I kept seeing it happening more and more to women and it wasnt talked about, she said. They just say, Oh, get the vaccine, which is great, but they dont talk about what getting the virus can do to pregnant women.

As a wedding planner, Butcher was surrounded by love. She found it with her husband, then in the daughter growing in her belly, who they named Emily after Butchers grandmother.

Read the original here:

God, No, Not Another Case. COVID-Related Stillbirths Didn't Have to Happen. - ProPublica

Posted in Covid-19 | Comments Off on God, No, Not Another Case. COVID-Related Stillbirths Didn’t Have to Happen. – ProPublica

Covid-19 Pandemic: Variation in Communication & Family Visiting Policies in Intensive Care – Physician’s Weekly

Posted: at 2:36 pm

For a study, researchers sought to conduct a web-based survey (MarchJuly 2021) to investigate ICU visiting practices before the pandemic, during the peak of COVID-19 ICU admissions, and at the survey response time. They sought information on visiting policies and modes of communication, including virtual visiting (videoconferencing). Investigators received 667 valid responses from ICUs across all continents. Before the pandemic, 20% (106/525) of facilities had unrestricted visiting hours, while 6% (30/525) did not permit in-person visits. At its peak, 84% (558/667) of facilities did not permit in-person visits for COVID-19 patients, compared to 66% for patients without the virus. This proportion had decreased to 55% (369/667) when the survey results were reported. About 53% (354/646) of respondents reported a government mandate restricting hospital visits. Most intensive care units (55%, 353/615) provided regular telephone updates; 50% (306/667) conducted formal meetings and discussions regarding prognosis or end-of-life via telephone. Virtual visiting was available in 63% (418/667) of instances at the time of the survey. During the epidemics early stages, extremely restricted visiting restrictions were implemented. These policies were gradually relaxed but did not revert to the standards before the pandemic. As a result, the telephone has overtaken virtual visits as the primary mode of patient communication in most intensive care units.

Source sciencedirect.com/science/article/pii/S088394412200079X

Go here to see the original:

Covid-19 Pandemic: Variation in Communication & Family Visiting Policies in Intensive Care - Physician's Weekly

Posted in Covid-19 | Comments Off on Covid-19 Pandemic: Variation in Communication & Family Visiting Policies in Intensive Care – Physician’s Weekly

What a Vaccine Researcher Wants You to Know About COVID-19 Boosters – Global Citizen

Posted: at 2:36 pm

The COVID-19 pandemic is not over. Despite the success of safety protocols and life-saving vaccines, vaccine inequality has allowed dangerous variants to develop, threatening the lives of people everywhere.

Now, the Centers for Disease Control and Prevention (CDC) warns that the BA.5 variant is now the dominant strain of COVID-19 in the United States and has led to a surge in cases and hospitalizations.

I completely understand the frustration and the pandemic fatigue; Im feeling it, and I know other health care professionals are too, Dr. Purvi Parikh told Global Citizen. But the reality of the situation is, the virus is still here and were still seeing a lot of new cases.

Parikh is an immunologist based in New York City, where shes been involved with the COVID-19 vaccine trials at New York University since the beginning of the pandemic. Over the past few months, she has personally diagnosed patients with COVID-19 every single day.

More than 78% of Americans are at least partially vaccinated, but the latest wave of cases is making it difficult to know who is most at risk of contracting a serious case of COVID-19. For this reason, Parikh spoke to Global Citizen about adjusting to life with COVID-19 and how booster shots can help end the pandemic globally.

According to a poll from the Pew Research Center conducted between January and May of this year, fewer Americans think COVID-19 is a major threat to public health than at the beginning of the pandemic. Meanwhile, current data about the BA.5 variant suggests that it is the most contagious strain of COVID-19, with the added bonus of being able to partially evade immunity from past infection and vaccination.

One thing I want to clarify (thats a big misconception) is that the current variant is not mild, Parikh said. We are seeing an uptick in hospitalizations and deaths, though mostly in unvaccinated individuals.

Pandemic fatigue has led some people to take risks they would not have taken before, such as forgoing masks or ignoring symptoms. Though fully vaccinated individuals may experience more protection than those who have not received a COVID-19 vaccine, the risks of contracting the virus still exist. This means that getting a booster shot is more important than ever.

Dont underestimate this virus even if youre fully vaccinated because everyones risk profile is different. If youre immunocompromised, elderly, have heart disease youre still at high risk, Parikh added.

Additional risks that come with contracting COVID-19 are becoming clearer as health care professionals learn more about the virus. Parikh, in particular, is studying long COVID, or the illness in which people who have recovered from COVID-19 experience lingering symptoms.

Some of Parikhs patients plagued by long COVID report neurological symptoms like brain fog, loss of taste and smell, and prolonged ringing in their ears. Others are experiencing extreme fatigue, difficulty breathing, heart palpitations, and nausea, months or years after their initial diagnosis of COVID-19.

Its only been two years so we dont really know the long-term effects [of COVID-19], Parikh said. But there are centers around the country studying long COVID.

Parikh shared that sensationalist headlines can make it seem like booster shots are futile when up against contagious subvariants, but the data doesnt lie. According to the CDC, hospitalization rates are 4.6 times higher for unvaccinated adults than for those who are up to date with their COVID-19 vaccination.

The boosters still protect you against hospitalization, death, and the people were mostly seeing getting admitted to hospitals havent gotten their boosters, or havent gotten vaccinated at all, Parikh said.

Like many other vaccines, the COVID-19 vaccines lose part of their efficacy over time, but that doesnt mean they arent effective at all. Ongoing research and clinical trials prove that receiving an additional dose of the vaccine after the initial two-shot series improves immunity, keeping people from getting extremely sick.

The doctor also pointed out that antibodies arent the only factors to consider when it comes to immunity.

T cells [which are part of the immune system] are much more important for fighting viruses than antibodies and are still very effective against the newer variants, she said. You need that T cell immunity to keep you off a breathing machine in the ICU, to keep you from dying, or from getting bad complications.

Guidance about the COVID-19 vaccines cannot rely on a one-size-fits-all approach, which is why Parikh underscored the importance of speaking with a physician about your personal risk of COVID-19. Depending on your age and health status, getting one or two booster shots may be the best way to protect yourself and others.

[Boosters shots] are very effective, especially if youre in a high risk group. Most people should have a third [dose of a COVID-19 vaccine], and some people should have a fourth depending on their risk profile, Parikh said.

Additionally, getting a booster shot now can help end the pandemic faster. According to Our World in Data, only 19.9% of people in low-income countries have received at least one dose of a COVID-19 vaccine, compared with 80% in wealthier nations. If COVID-19 continues to spread globally, newer variants will keep developing, putting more people at risk.

One of my favorite sayings from the UN Foundation is: An outbreak anywhere is an outbreak everywhere. This pandemic is case in point, Parikh said. The quicker everyone gets their vaccine, the quicker everyone is protected.

COVID-19 has been a scary, daily part of life for the past two years. While we cant let our guard down just yet, its important to recognize just how far weve come.

Were in a much better place than we were two years ago, Parikh said. If someone is diagnosed with COVID, I can treat them with an antiviral right away.

She added: The other good news is the vaccine. If you get sick, [being vaccinated] reduces your chances of death and hospitalization significantly.

Parikh also shared that clinical trials are continuously taking place, helping health care professionals get one step closer to ending the pandemic. Until we get there, however, we all have to do our part to protect each other.

Be up to date with your vaccines, whether thats with one booster or two boosters. Wash your hands, wear a high quality mask, and have a plan in place if you get sick because we do have the tools to fight this virus, she said. If you take these precautions, you can still live your life normally.

This article is part of a series focused on vaccine hesitancy funded by the Rockefeller Foundation.

More:

What a Vaccine Researcher Wants You to Know About COVID-19 Boosters - Global Citizen

Posted in Covid-19 | Comments Off on What a Vaccine Researcher Wants You to Know About COVID-19 Boosters – Global Citizen

COVID-19 at its worst killed one-in-five it hospitalized in Pa., new data shows – PennLive

Posted: at 2:36 pm

During Pennsylvanias first big COVID-19 wave, nearly 20% of hospital patients who had it died. That figure, from April of 2020, represents the peak in-hospital mortality rate for COVID-19 in Pennsylvania through the end of 2021.

The hospital mortality rate varied going forward, dropping to around 8% in July of 2020 and April of 2021, but rising above 13% during the winter surges of 2020 and 2021. It was nearly 15% as recently as recently as the fall of 2021.

The data comes from the Pennsylvania Health Care Cost Containment Council, a state agency that collects health care information. The PHC4 doesnt provide medical explanations for the data and things like variations in the mortality rate.

The figures cover the period from the start of COVID-19 related hospitalizations in early 2020 to the end of 2021. During that period, the highest number of hospitalizations in any month, about 25,000, took place in December of 2020.

The data show breathing ventilator use was highest in the spring of 2020, with about 16% of COVID-19 patients put on ventilators. The rate was about 11% in late 2021 as Pennsylvania faced another big wave of cases and hospitalizations.

The data, which can be read here, reflect various characteristics of COVID-19 patients such as age, sex and race.

During the final three months of 2021, nearly 40,000 people with COVID-19 were hospitalized. However, an unknown number tested positive for COVID-19 at the hospital, but may have been hospitalized for other reasons and not significantly affected by COVID-19.

A rose is placed on the casket of Gerald Welch, a Harrisburg school board member who died of COVID-19 in spring 2020.(Sean Simmers | ssimmers@pennlive.com, file)

During that period, 14.6% of the patients died in the hospital. The average hospital stay was 8.2 days. The hospitalizations included 770 people 18 or younger, with those patients having a 1.3% mortality rate and 6.1% needing ventilators.

The highest mortality rate involved people over 85, with 20% dying in the hospital. The most hospitalizations involved people 65-74, with nearly 9,000 hospitalized during the last three months of 2021, and about 18% dying.

Overall, more men than women ended up in the hospital with COVID-19; 16% of the men died, compared to 13% of women.

As of Aug. 1, Pennsylvania had a total of 46,164 COVID-19 deaths, according to tracking by Johns Hopkins University. The state was averaging 16 deaths per day as of early August, well below the peak of about 220 in early 2021.

In general, doctors say vaccination and improvements in treatment including new drugs that can prevent infected people from becoming severely ill have substantially decreased the chances of dying from COVID-19.

More:

Penn State is changing its guidelines on COVID quarantine, isolation ahead of fall semester

See the article here:

COVID-19 at its worst killed one-in-five it hospitalized in Pa., new data shows - PennLive

Posted in Covid-19 | Comments Off on COVID-19 at its worst killed one-in-five it hospitalized in Pa., new data shows – PennLive

Hyundai and Kia Take on Space Exploration IoT World Today – IoT World Today

Posted: at 2:35 pm

The agreement marks the first step in the companies mission to expand robotics capabilities beyond Earth

Hyundai and its sister company Kia have partnered to develop mobility solutions for lunar exploration; building on Koreas national space program and seeking to progress the nations space exploration industry.

The agreement has been heralded as a seminal moment in the automotive companies mission to expand their reach beyond Earth.

We have taken the first step towards transforming our vision for robotics and the concept of Metamobility into reality, said Yong Wha Kim, executive vice president of Hyundai Motor and Kia. We will expand the scope of human movement experience beyond traditional means of transport and beyond the bounds of Earth to further contribute to the progress of humankind and help create a better future.

The news also follows Koreas successful launch in June of a domestically designed and produced rocket, developed to launch a satellite and indicating the nations growing aerospace ambitions.

For the space mobility initiative, the automotive companies formed a consortium with six Korean research institutes to research and develop not only the mobility system itself but also technologies to send the vehicle to the moon and remotely operate it once its in place.

While these participating bodies will contribute their engineering and space expertise, Kia and Hyundai will provide their smart mobility technologies; combined to create not only space mobility solutions but also exploration equipment, remote communication tools and software for mobility operation.

Hyundai Motor announced its robotics vision of Metamobilty in January, envisioned to help fulfill unlimited mobility by expanding robotics and AI solutions to space and using robotics as a medium between real and virtual worlds. Hyundai is also set to introduce a new Mobility of Things (MoT) concept, whereby robotics will grant typically inanimate object mobility using plug-and-play platforms.

Here is the original post:

Hyundai and Kia Take on Space Exploration IoT World Today - IoT World Today

Posted in Space Exploration | Comments Off on Hyundai and Kia Take on Space Exploration IoT World Today – IoT World Today

NASA: When does Artemis I launch? Will Artemis I go to the moon? – Deseret News

Posted: at 2:35 pm

Excitement is building at Kennedy Space Center in Florida as NASA prepares to launch an unmanned spacecraft called Orion on a 42-day mission that will take the United States a step closer to once more landing on the moon.

A series of launches under the banner Artemis are planned, beginning with Artemis I, scheduled for Aug. 29 at 8:33 a.m. ET. Based on hotel and airline reservations, observation ticket sales and other factors, the prediction is that well over 100,000 people will watch in person nearby from specially designated parking lots to areas designed for the purpose in and atop area hotels, among other locations.

If the launch is delayed by weather or for technical reasons, the next possible launch would be Sept. 2 or Sept. 5. Beyond that, there are several opportunities before the end of the year.

Artemis II will duplicate Artemis Is journey, but with astronauts. The actual moon landing by two astronauts is expected with Artemis III in late 2025, NASA officials said in a press briefing Wednesday that was carried on NASAs Twitter page. They said that the launch of the unmanned spacecraft is a test flight that will stress Orion more than could be done with a crew on board, since the spacecraft has not been flown before.

They described a lean-forward strategy that will allow risks they would not be willing to take with a manned flight, including with the go/no-go decision on the actual launch. We are trying to buy down risk. Were willing to take more risks than we would on later test flights, an official said.

The mission is slated to last six weeks to allow for all kinds of maneuvers as the rocket orbits the moon to perform tests.

According to the Kennedy Space Center, Artemis I is the first test of NASAs deep space exploration systems, with theOrion spacecraftlaunching atop the massiveSpace Launch Systemrocket. This mission is the first in a series of missions to demonstrate NASAs ability to extend human existence to the Moon and beyond.

The spacecraft, Orion, takes its name from the largest constellation in the night sky, according to NASA.

Rollout of the 32-story-tall Space Launch System rocket and its Orion crew capsule marks a key milestone in U.S. plans for renewed lunar exploration after years of setbacks, and the publics first glimpse of a space vehicle more than a decade in development, Reuters reported of launch pad tests in March.

The SLS-Orion, which cost some $37 billion to develop including ground systems, constitutes the backbone of the NASAs Artemis program, aimed at returning astronauts to the moon and establishing a long-term lunar colony as a precursor to eventual human exploration of Mars, the article said.

According to USA Today, NASAs moon-focused Space Launch System rocketstands 322 feet tall and promises to be the biggest, most powerful rocket to launch from Floridas Space Coast in years bringing with ita level of excitement to match.

Recent SpaceX Crew Dragon launches that take astronauts to the International Space Station from the space center have drawn as many as a quarter-million visitors, PeterCranis,executive director of theSpace Coast Office of Tourism, told USA Today.

I think the crewed launchesand these Artemis launchesare going to be of equal interest to people, Cranis said. I would expect certainly over 100,000, if not more, coming for that.

We are expecting capacity crowds at Kennedy Space Center Visitor Complex for the upcoming Artemis launch, saidTherrin Protze, the visitor complexs chief operating officer, according to Florida Today. (The visitor complex)will offer special Artemis launch viewing packages that will include some of the closest public viewing opportunities with distinctive experiences like live commentary from space experts and access to select exhibits and attractions.

The article said area hotels are offering spaced-themed deals and some are sold out while others are selling out fast.

Meanwhile, the space center is selling viewing packages online that provide access to special locations in designated parking lots 8 miles from the launch pad. The tickets are $99 a person. You will see the launch as soon as the rocket clears the tree line, according to the ticket page.

Theyre reportedly selling fast.

Link:

NASA: When does Artemis I launch? Will Artemis I go to the moon? - Deseret News

Posted in Space Exploration | Comments Off on NASA: When does Artemis I launch? Will Artemis I go to the moon? – Deseret News

Europe’s troubled Mars rover still vital in the search for life on the Red Planet – Space.com

Posted: at 2:35 pm

The stars have not been aligned for Europe's first Martian rover ExoMars, but scientists still think the aging vehicle can play a big role in answering one of the biggest questions in Mars exploration: has there ever been life on the Red Planet?

The European Space Agency's (ESA) ExoMars Rosalind Franklin Rover is probably the most high-profile space industry casualty of Russia's war in Ukraine. Originally expected to launch in 2018, the rover was finally declared ready to go (after several delays) for a launch in September this year atop Russia's Proton rocket from the Baikonur Cosmodrome in Kazakhstan. But Russia's invasion of Ukraine put a stop to these plans.

ESA officially terminated cooperation on the ExoMars mission with Russia in July, leaving the rover, conceived in 2004, once again in limbo, and more importantly, without a landing platform to place it on the surface of Mars. (That landing platform was built by Russia, who joined the ExoMars program in 2012 following the withdrawal of the original partner, NASA, in 2012.)

ESA has yet to decide on the mission's fate. Having spent $1.3 billion on the program already, it will have to choose between scrapping the rover altogether or forking out another substantial sum to replace the Russian bits.

Related: A brief history of Mars missions

In the case of the latter option, the most optimistic estimates see the ExoMars rover leaving Earth in 2028. For many European scientists, scrapping the mission should not be an option at all, and not just because of the investment. Even though NASA's Perseverance has been smashing its sample collection targets, and plans for a mission that would bring those samples to Earth are already underway, there is a lot the aging ExoMars rover can contribute to our understanding of Mars, they say. And some of those questions, in fact, cannot be answered by the stellar Perseverance.

"[The rover's instruments] are going to get a bit old," John Bridges, a professor of planetary science at Leicester University in the U.K., told Space.com. "But as long as the maintenance can be done, it doesn't actually bother me too much that we're not using the most cutting-edge technology. Even if we're going by bicycle rather than by the newest car, it doesn't really matter, as long as we get there."

The biggest strength, and scientific promise, of the Rosalind Franklin ExoMars rover is its 6.6-foot (2 meters) drill, which, according to some astrobiologists, may have a higher chance of finding traces of past or present Martian life on Mars than the agile Perseverance.

"The rock pieces that Perseverance collects are from the immediate surface [of Mars]," Susanne Schwenzer, an astrobiologist at Open University in the U.K., who is also an interdisciplinary scientist on the ExoMars mission and a member of the science teams of NASA's Curiosity and the Mars Sample Return missions, told Space.com. "And this immediate surface is bombarded by galactic cosmic rays, and the UV rays [from the sun], which destroy organic materials."

Unlike Earth, Mars has no protective magnetic field and a very thin atmosphere, so there is nothing to filter this sterilizing radiation, some of which can penetrate several meters deep into the Martian rocks.

"[The effects of the radiation] diminish exponentially, so the first centimeters [inches] are the worst hit," Schwenzer said.

That doesn't mean that Perseverance cannot find traces of life, just that detecting the organic molecules in the burnt surface layers might require a more challenging scientific analysis, Schwenzer added.

"The advantage of the return samples is that we will have them in our labs over here," Schwenzer said. "If we find something that we can't answer with the instruments that we have, we can wait for the right technology to be developed. It took until the late 1990s to find water in the Apollo samples because they didn't have the right instrumentation at that time."

The deep excavations that the ExoMars rover was built for can, in fact, help scientists understand Perseverance's rocks and the alteration they underwent due to the bombardment by radiation.

"[The ExoMars rover] will help us understand how the organics degrade with depth or do not degrade and are preserved at deeper layers," Schwenzer said.

Bridges agrees with Schwenzer. But there are other reasons why continuing with ExoMars should be the only option on the table, he thinks. A generation of European scientists has tied their careers with the mission, which may have always been a bit of a moonshot for Europe, ever since its inception in 2004.

"When we started ExoMars in 2004, it was way off the capabilities [of ESA and the European space industry] to do it," Bridges said. "So we got the Americans in to land it and when the Americans pulled out, ESA just looked around, and the Russians put up their hand, and it was done."

Bridges describes the partnership with Russia, hastily put together by ESA leadership under General Director Jean-Jacques Dordain in 2012, as "a strategic mistake."

"I think we should have hit the pause button back then and have a harder discussion across the European communities about what we were going to do," he said.

At that time, the onset of the conflict in Ukraine was still two years away, but Russia was already guilty of stirring a bloody war in Georgia (opens in new tab); its actions in the Caucasian country were overwhelmingly overlooked by the international community at that time.

"There's frustration and disappointment, because so much work has gone into ExoMars," Bridges said. "The instruments, the science teams. But we should probably still stick with it and try and recoup all that scientific investment, not just throw up our hands in disappointment and walk away from it."

Schwenzer adds that to provide the ultimate answer to the big question, whether there has ever been life on Mars, scientists would want to review as much data as possible.

"Extraordinary claims require extraordinary evidence," Schwenzer said, quoting famous astrobiologist Carl Sagan. "We can't just find one molecule that is usually produced by life on Earth and claim that we have found life on Mars. We can't make that claim unless we can absolutely exclude that anything else could have made that molecule. And in order to do that, we would need all the information that we can get, not just that from one mission."

ExoMars' projected landing site in Oxia Planum, an ancient clay-rich basin near Mars' northern tropic, was carefully selected by a pan-European scientific consortium as it offers the best conditions to harbor traces of life.

Formed about 4 billion years ago, the basin, covered with fine-grained sediments, has a catchment area of thousands of miles, Bridges said, where water in the past used to accumulate.

"It's a very different area to Jezero Crater [where Perseverance roams]," Bridges said. "But because we have seen one, that doesn't mean that it is not worth going to see the other. We have still only explored a tiny fraction of the Martian surface and we shouldn't fall into the trap of assuming that we've seen that, done that."

The ExoMars conundrum, Bridges suggests, highlights weaknesses in ESA's strategy, and undermines the agency's aspiration to be the world-class player it desires to be.

ESA, a partnership of 22 European member states, was beaten to the surface of Mars by China, which only revealed its plans for the Zhurong rover in 2014. Chinese landers, including the famous Yutu rover, have dominated moon exploration in the past decade. Japan's space agency JAXA, in the meantime, has built a legacy of returning samples from asteroids.

"ESA has this problem that they can be left flapping in the breeze a bit," Bridges said. "If external factors change, they don't seem to quite have the size or strength to withstand being buffeted about. Part of that is because they haven't really decided what their strategy is, what they really want to be doing, compared to JAXA or China's National Space Administration, who know exactly what they want to do and they just get on and do it."

ESA is currently evaluating options for the ExoMars rover, which it will present to its member states later this year. Among the possibilities is a return to the original partner NASA, who could land the rover using its proven technologies, Bridges said, but with a substantial financial contribution from ESA.

NASA's recent decision to scrap the European Mars sample return fetch rover and replace it with NASA-built helicopters, may provide an impetus to stick with the troubled ExoMars.

Follow Tereza Pultarova on Twitter @TerezaPultarova. Follow us on Twitter @Spacedotcom and on Facebook.

Read more from the original source:

Europe's troubled Mars rover still vital in the search for life on the Red Planet - Space.com

Posted in Space Exploration | Comments Off on Europe’s troubled Mars rover still vital in the search for life on the Red Planet – Space.com